Chemistry:Andamertinib
From HandWiki
Andamertinib is an investigational new drug that is being develop by Avistone Biotechnology Co., Ltd. for the treatment of non-small-cell lung cancer (NSCLC). It is an epidermal growth factor receptor (EGFR) antagonist.[1][2][3]
Andamertinib is an irreversible EGFR inhibitor designed to target EGFR with exon 20 insertion mutations.[4]
Clinical trials
The following clinical trials are evaluating andamertinib for treating NSCLC:
- phase 2 (on going)[5]
- phase 2 (on going) in combination wth vebreltinib or osimertinib[6]
- phase 3 (recruiting) in combination with vebreltinib or pemetrexed plus carboplatin or cisplatin[7]
References
- ↑ "Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study". Journal of Thoracic Oncology 21 (3): 103518. March 2026. doi:10.1016/j.jtho.2025.11.008. PMID 41248848.
- ↑ "Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches". Nature Reviews. Clinical Oncology 23 (1): 63–83. January 2026. doi:10.1038/s41571-025-01085-z. PMID 41219394.
- ↑ "Andamertinib - Avistone Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800068366.
- ↑ "Andamertinib | Ligand page". IUPHAR/BPS Guide to PHARMACOLOGY. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13732.
- ↑ Clinical trial number NCT07336732 for "Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations" at ClinicalTrials.gov
- ↑ Clinical trial number NCT06574347 for "Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC." at ClinicalTrials.gov
- ↑ Clinical trial number NCT06970782 for "Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure" at ClinicalTrials.gov
 |  |
